Fig. 4From: Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agentsRAB15 transfection and cellular drug sensitivity. RAB15 transfection to BICR6 cells provided 2 stable transfectants with having different levels of RAB15 overexpression (#7 and #10), which was shown as the results obtained in Western blot analyses and the following quantification assay on the blots (A) (See Supplemental Information File 1_Western Blot Raw Data). Although IC 50 values of TXT in the transfectant #7 were increased in accordance with an increase of RAB15 expression, such expression-drug sensitivity interaction was not observed in BICR6 variant #10 (A, B). Unexpectedly, the enhanced expression of RAB15 led to an enhancement of cellular CDDP (cisplatin) resistance in the transfectant #7 but did not in BICR6 variant #10 in the similar manner with TXT (A, C)Back to article page